Greg Duncan

Background

About Greg Duncan

Multiple time CEO tasked with setting the strategic direction for corporate entities focused on developing and commercializing new drug candidates to treat a wide range of diseases categories, including inflammation, infection, cancer, neurologic, pain, cardiovascular, specialist and rare conditions. • Successful track record of fund raising, scaling both public and private capital, as well as executing an initial public offering. • Strong communicator who has effectively represented Pfizer (symbol: PFE), UCB (UCB.BR) Virios Therapeutics Inc.(VIRI), and Celtaxsys to the investment community, both in the US and in Europe. • Executive Committee member and Independent Board Director at both public and private companies. • Extensive experience managing R&D programs and portfolio investments to improve pipeline value at PFE, UCB, Celtaxsys and Virios Therapeutics, Inc. • Proven track record of achievement including managing $1.5+B P&L, while delivering profitable growth and driving operational improvement in all regions (i.e. US, LATAM, EU APAC and AfME). • Successful builder of highly talented, diverse senior management teams and effective leader of organizations as large as colleagues across all functions. • Extensive operational experience maximizing in-market performance of both ethical (large and small molecule, prescription and in-office utilization) and OTC product portfolios. Notable launch/commercialization experience includes category leading brands such as Lipitor, Zoloft, Aricept, Viagra, Celebrex, Lyrica, Rebif, Cimzia, Vimpat and Sutent.